Drug websites including GoodRx (GDRX) will not be partnering with TrumpRx, CBS News’ Jennifer Jacobs reports, citing sources. One official said the federal government website will send consumers to the pharmaceutical companies’ websites, where they can buy prescription medicines directly, and the companies will decide how to fulfill those orders, the author notes.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx Holdings: Balancing Challenges and Opportunities Amidst PTR Growth Concerns and Pharma Manufacturing Strength
- GoodRx price target lowered to $4 from $4.25 at UBS
- GoodRx price target lowered to $4 from $5 at Mizuho
- Challenging Outlook for GoodRx Holdings Amid Structural and Market Pressures
- Buy Rating for GoodRx Holdings: Strategic Initiatives and Growth Prospects Amid Challenges